Medical Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
T |
|---|
T cellA type of white blood cell. T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. Also called T lymphocyte and thymocyte1.
| |
Targeted therapyA type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Some targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells. Other types of targeted therapies help the immune system kill cancer cells or deliver toxic substances directly to cancer cells and kill them. Most targeted therapies are either small molecule drugs or monoclonal antibodies1. BRAF-targeted therapy:Targeted therapy is medication that interferes with the function of abnormal molecules within cancer tumour cells that regulate their growth. The goal of targeted therapy is to shut down the mutated molecules to slow the growth of melanoma cells—without harming healthy tissue. About half of all melanoma cells have genetic mutations in the BRAF (pronounced bee-raf) protein. BRAF and MEK, another protein, are molecules that help regulate cell growth. A BRAF mutation triggers cells to develop abnormally and divide out of control. Targeted therapy drugs block the activity of the MEK protein and the mutated BRAF protein. In this way, the drugs slow or stop the growth and spread of melanoma2. | |
TelomeraseAn enzyme in cells that helps keep them alive by adding DNA to telomeres (the ends of chromosomes). Each time a cell divides, the telomeres lose a small amount of DNA and become shorter. Over time, the chromosomes become damaged and the cells die. Telomerase helps keep this from happening. Cancer cells usually have more telomerase than most normal cells1. | |
TelomereThe end of a chromosome. Telomeres are made of repetitive sequences of non-coding DNA that protect the chromosome from damage. Telomeres become shorter each time the cell divides.1 | |
TERTA gene that makes a protein involved in maintaining telomeres (the ends of chromosomes). Mutations (changes) in the TERT gene have been found in some types of cancer, including melanoma, acute myeloid leukaemia, breast cancer, and cholangiocarcinoma (cancer that forms in the bile ducts). Mutations in the TERT gene have also been found in a rare, inherited condition called dyskeratosis congenita, which causes abnormal changes in the skin and nails and white patches inside the mouth. People with this condition have an increased risk of bone marrow failure (a condition in which the bone marrow does not make enough blood cells), myelodysplastic syndrome, pulmonary fibrosis (scarring of the lungs), and certain types of cancer1.
| |
Thin melanomaThin melanoma is defined as less than 1 mm in thickness using the Breslow method for measuring melanomas under the microscope23. | |
Threonine | |
ThymineThymine is a chemical compound that is used to make one of the building blocks of DNA. It is a type of pyrimidine1. Thymine (T) is one of four chemical bases in DNA, the other three being adenine (A), cytosine (C), and guanine (G). Within the DNA molecule, thymine bases located on one strand form chemical bonds with adenine bases on the opposite strand. In the double helix, thymine pairs with adenine, or the A nucleotide. The sequence of four DNA bases encodes the cell's genetic instructions24.
| |
TissueA group or layer of cells that work together to perform a specific function1.
| |
TNM Staging SystemThe system to describe the amount and spread of cancer in a patient’s body, using TNM. T describes the size of the tumour and any spread of cancer into nearby tissue; N describes spread of cancer to nearby lymph nodes; and M describes metastasis (spread of cancer to other parts of the body). This system was created and is updated by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC). The TNM staging system is used to describe most types of cancer. Also called AJCC staging system. pTNM means that the stage has been determined with the help of a pathologist1.
| |
TranscriptionIn biology, the process by which a cell makes an RNA copy of a piece of DNA. This RNA copy, called messenger RNA (mRNA), carries the genetic information needed to make proteins in a cell. It carries the information from the DNA in the nucleus of the cell to the cytoplasm, where proteins are made. 1 | |
TumourAn abnormal mass of tissue that forms when cells grow and divide more than they should or do not die when they should. Tumours may be benign (not cancer) or malignant (cancer). Benign tumours may grow large but do not spread into, or invade, nearby tissues or other parts of the body. Malignant tumours can spread into, or invade, nearby tissues. They can also spread to other parts of the body through the blood and lymph systems. Also called neoplasm1. Any abnormal swelling in or on a part of the body. The term is usually applied to an abnormal growth of tissue, which may be benign or malignant22.
| |
Tumour heterogeneityTumour heterogeneity describes the observation that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation, and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity). A minimal level of intra-tumour heterogeneity is a simple consequence of the imperfection of DNA replication: whenever a cell (normal or cancerous) divides, a few mutations are acquired leading to a diverse population of cancer cells27. | |
Tumour in situ (Tis)Melanoma cells that remain in the place where they first formed. They have not spread. Also called stage 0 disease. | |
Tumour Infiltrating Lymphocytes (TILs)Tumour infiltrating lymphocytes (TILs) are white blood cells that have left the bloodstream and migrated towards a tumour. They include T cells and B cells and are part of the larger category of ‘tumour-infiltrating immune cells’. A type of immune cell that has moved from the blood into a tumour. TILs can recognize and kill cancer cells. In cancer therapy, TILs are removed from a patient’s tumour, grown in large numbers in a laboratory, and then given back to the patient to help the immune system kill the cancer cells. Also called tumour-infiltrating lymphocyte. 1 | |
Tumour Infiltrating Lymphocytes BriskThe lymphocytic response is subdivided into three categories - brisk, non-brisk, or absent. BRISK: TILs are present throughout the vertical growth phase or across the entire base of the tumour. It is usually seen in thin melanomas. The presence of a brisk infiltrate is a favourable prognostic result in primary melanoma. | |
Tumour Infiltrating Lymphocytes Non-BriskThe lymphocytic response is subdivided into three categories - brisk, non-brisk, or absent. NON-BRISK: TILs focally infiltrate the tumour. | |
Tumour suppressor genesGenes that inhibit expression of the tumourigenic phenotype. They are normally involved in holding cellular growth in check. When tumour suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible24. A tumour suppressor gene directs the production of a protein that is part of the system that regulates cell division. The tumour suppressor protein plays a role in keeping cell division in check. When mutated, a tumour suppressor gene is unable to do its job, and as a result uncontrolled cell growth may occur. This may contribute to the development of a cancer24. Within our genome is a class of genes called tumour suppressor genes. These genes make proteins that act like brakes within the cell, and when they're turned on they actually prevent the cell from dividing. However, if a tumour suppressor gene is lost or mutated in a very specific way so that it loses its activity, the cell can then start to divide uncontrollably, and this contributes to the development of cancer. So the inactivation of tumour suppressor genes is one type of genetic alteration that contributes to tumour genesis. "Tumour genesis" is the technical term for the development of cancer24.
| |
Tumoural | |